Tag: Cancer: Lymphoma
Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
Nonrelapse mortality was driven by ICANS in early follow-up period, followed by infection through three months
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
Reduction seen in hypogammaglobulinemia, infections or severe infections, and associated antimicrobial use
Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
Significant overall survival benefit seen for Glofit-GemOx at primary and follow-up analysis
ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma
Complete responses seen in 38 percent of patients, all with non-GCB DLBCL, high-grade B-cell lymphoma with rearrangements of MYC and BCL2 or BCL6
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy
Lethal T-cell lymphoma identified in one patient who received axicabtagene ciloleucel therapy for diffuse large B-cell lymphoma
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
Six of 10 patients remained in minimal residual disease-negative complete remission after treatment
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
Women have increased risk for thyroid, renal, lung cancers; men have highest risk for melanoma, bladder, prostate cancers
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
20 percent of patients treated with Breyanzi achieved a complete response
Risk Stratification Can Predict Outcomes for CAR T-Cell Therapy in Lymphoma
Stratification based on prelymphodepletion C-reactive protein, ferritin can classify patients into high, intermediate, and low risk
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
